Abstract S3-03: Nuclear FGFR1 interaction with estrogen receptor (ER) {alpha} is associated with resistance to endocrine therapy in ER+/FGFR1-amplified breast cancer

Conclusions: These data support a critical role of ER and FGFR1 interaction in endocrine resistance in ER+/FGFR1-amplified breast cancer. Targeting of FGFR1 in combination with antiestrogens may abrogate resistance to endocrine therapy in these tumors and is worthy of clinical investigation.Citation Format: Formisano L, Young CD, Bhola NE, Bulen B, Estrada VM, Wagle N, Van Allen E, Red Brewer ML, Jansen VM, Guerrero AL, Giltnane JM, Strcker T, Arteaga CL. Nuclear FGFR1 interaction with estrogen receptor (ER) α is associated with resistance to endocrine therapy in ER+/FGFR1-amplified breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr S3-03.

Source: Cancer Research - February 18, 2016 Category: Cancer & Oncology Authors: Formisano, L., Young, C., Bhola, N., Bulen, B., Estrada, V., Wagle, N., Van Allen, E., Red Brewer, M., Jansen, V., Guerrero, A., Giltnane, J., Strcker, T., Arteaga, C. Tags: General Session Abstracts Source Type: research